Who is sponsoring NCT05090371?

NCT05090371 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05090371?

Interventions in NCT05090371: Ofatumumab, Disease modifying treatment (DMT).

What condition does NCT05090371 study?

NCT05090371 studies Relapsing-Remitting Multiple Sclerosis.

Is NCT05090371 still recruiting?

NCT05090371 is currently active, enrolled. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT05090371: SOSTOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Active, enrolled Phase 4 Last updated 30 March 2026

What this trial tests

Phase 4 trial testing Ofatumumab in Relapsing-Remitting Multiple Sclerosis in 136 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 March 2022

Primary endpoint
13 April 2027

13 April 2027

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	136
Start date	2 March 2022
Primary completion	13 April 2027
Estimated completion	13 April 2027
Sites	43 locations across Canada, United States

Drugs / interventions tested

Ofatumumab (OFATUMUMAB) — full drug profile →
Disease modifying treatment (DMT) — full drug profile →

Conditions studied

Relapsing-Remitting Multiple Sclerosis — all drugs for Relapsing-Remitting Multiple Sclerosis →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 50, any sex, with Relapsing-Remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

B cell targeted therapies in inflammatory autoimmune disease of the central nervous system.
Furman MJ, Meuth SG, Albrecht P, Dietrich M, et al · · 2023 · cited 24× · PMID 36969208 · DOI 10.3389/fimmu.2023.1129906
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, Lucenteforte E, et al · · 2023 · cited 10× · PMID 38032059 · DOI 10.1002/14651858.cd012186.pub2
Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials.
Schilke ED, Remoli G, Funelli E, Galimberti M, et al · · 2024 · cited 7× · PMID 38117403 · DOI 10.1007/s10072-023-07228-3
What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study.
Taj HM, Talib M, Siddiqa S, Sarfraz A, et al · · 2022 · cited 1× · PMID 36360540 · DOI 10.3390/healthcare10112199

Verify or expand the search:

Other trials of Ofatumumab

Trials testing the same drug.

NCT06486779 — Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study · recruiting
NCT06867991 — Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis · Phase 3 · recruiting
NCT06345157 — ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients · active not recruiting
NCT07353216 — Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Se · recruiting
NCT05809986 — Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study · recruiting

Other recruiting trials for Relapsing-Remitting Multiple Sclerosis

Currently open trials in the same condition.

NCT05123703 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Re · Phase 3 · active not recruiting
NCT04530318 — Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis · Phase 2 · active not recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05090371 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05090371.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing